Using a scoring system could allow health systems and pharmacies to identify a range of manufacturers who can meet their supply needs, potentially at a lower cost. (Photo: Shutterstock)
How effective is that generic drug you just picked up from the pharmacy? The regulations governing the approval of bo-similars has led to a perception that all generic drugs are created equal, when, in fact, that's not necessarily the case. Generic drugs are increasingly being manufactured overseas, where oversight and regulations are much more lax.
Pointing to a long list of drug quality issues that includes contamination of critical blood pressure medications, heartburn medications and diabetes medications with carcinogens (have you gotten around to throwing out that bottle of Zantac yet?), a group of pharmacists is calling for the creation of a quality score system.
"Not only do drug quality issues place patients' lives at risk, they also account for over 60% of drug shortages and generate fear and mistrust that is an important cause of medication non-adherence," they write in a recent paper. Consumers who are given a drug of the wrong dose or one that does not work as intended risk serious health consequences.
In recognizing the need for greater transparency, the FDA has encouraged a voluntary rating system for drug manufacturers, and the pharmacists, in their paper, outline what such a system should include. Their system would use evidence-based criteria to score drugs on a scale of 0 to 100, with 100 being the expected "default" or standard based on the FDA's approved "Current Good Manufacturing Practices."
"The intended use of the proposed quality scores system in an established healthcare system would be to inform and enable pharmacy procurement teams so that decision trees could be enacted," the pharmacists write. Higher quality drugs would be categorized as "green" and would be the first choice for use. Mid-level, or "yellow" products should be considered if the price difference compared to a "green" alternative is significant, and "red" should be avoided at all costs.
Using such a method could allow health systems and pharmacies to identify a range of manufacturers who can meet their supply needs, potentially at a lower cost. Having a list of high-quality alternatives can also alleviate drug shortages, the authors note.
"Even if a health system is unable or uninterested to add any additional purchasing cost or add any potential drug shortage burden, it is highly likely that the use of the proposed quality score system will provide a significant benefit in avoiding low-quality drug products," the authors add.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Emily Payne
Emily Payne is director, content analytics for ALM's Business & Finance Markets and former managing editor for BenefitsPRO. A Wisconsin native, she has spent the past decade writing and editing for various athletic and fitness publications. She holds an English degree and Business certificate from the University of Wisconsin.
